CLAIMS

1. A method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising:

a. cultivation of mycoplasma bacteria in a serum-reduced, eukaryotic cell system comprising MDCK or McCoy cells, wherein said mycoplasma bacteria is M. *hyorhinis*;

b. obtaining an antigen of the mycoplasma bacteria, wherein the antigen is a whole inactivated bacterin; and

c. addition of a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein the serum is free of swine serum.

3. The method of claim 1, wherein the mycoplasma bacteria are cultivated in the absence of serum.

4. The method of any one of claims 1 to 3, wherein the immunogenic composition is a mycoplasma immunogenic composition.

5. The method of claim 1, wherein the whole inactivated bacterin is formalin inactivated bacterin.

6. The method of any one of claims 1 to 5, wherein said immunogenic composition is formulated for a single-dose administration.

7. The method of any one of claims 1 to 6, wherein said subject is a swine.

8. The method of any one of claims 1 to 6, wherein said subject is cattle.

9. The method of any one of claims 1 to 6, wherein said subject is a cat.

10. The method of any one of claims 1 to 6, wherein said subject is a dog.

11. The method of any one of claims 1 to 10, wherein said pharmaceutically acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, adjuvants, immune stimulants, and combinations thereof.

12. The method of claim 11, wherein said pharmaceutically acceptable carrier is an adjuvant selected from the group consisting of aluminum hydroxide, aluminum phosphate, saponins, water-in-oil emulsion, oil-in- water emulsion, water-in-oil-in-water emulsion, polymers of acrylic or methacrylic acid, copolymers of maleic anhydride and alkenyl derivative, the RIBI adjuvant system, Block copolymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314, muramyl dipeptide, and combinations thereof.

13. The method of claim 12, wherein said pharmaceutically acceptable carrier is a water-in-oil-in-water emulsion or a carbomer.